{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:11:19Z","timestamp":1770495079359,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"DOI":"10.7759\/cureus.25766","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T21:44:52Z","timestamp":1654724692000},"source":"Crossref","is-referenced-by-count":1,"title":["A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors"],"prefix":"10.7759","author":[{"given":"Nataliia","family":"Lopina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Dmytrenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Hamov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Lopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Dyagil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142877","article-title":"Innovation in hematology. Perspectives: CML 2016","volume":"101","author":"Hehlmann R","year":"2016","unstructured":"Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016, 101:657-9. 10.3324\/haematol.2016.142877","journal-title":"Haematologica"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber MC","year":"2017","unstructured":"Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017, 2017:110-4. 10.1182\/asheducation-2017.1.110","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16971","article-title":"A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia","volume":"191","author":"Smith G","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, et al.. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020, 191:171-93. 10.1111\/bjh.16971","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.04.009","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring","volume":"43","author":"Seguro FS","year":"2021","unstructured":"Seguro FS, Silva CM, Moura CM, et al.. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. Hematol Transfus Cell Ther. 2021, 43:191-200. 10.1016\/j.htct.2020.04.009","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.011","article-title":"Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States","volume":"17","author":"Coutinho AD","year":"2017","unstructured":"Coutinho AD, Makenbaeva D, Farrelly E, Landsman-Blumberg PB, Lenihan D. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States. Clin Lymphoma Myeloma Leuk. 2017, 17:676-83. 10.1016\/j.clml.2017.06.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson RA","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, et al.. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012, 26:2197-203. 10.1038\/leu.2012.134","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016, 30:1044-54. 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes JE","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013, 369:1783-96. 10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018, 132:393-404. 10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes JE","year":"2017","unstructured":"Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017, 17:78-82. 10.1016\/j.clml.2016.09.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain P","year":"2019","unstructured":"Jain P, Kantarjian H, Boddu PC, et al.. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019, 3:851-61. 10.1182\/bloodadvances.2018025874","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab043","article-title":"Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study","author":"Yang YC","year":"2021","unstructured":"Yang YC, Huang RY, Tsai HJ, Li PC, Yang YH, Hsieh KP. Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study. Eur J Prev Cardiol. 2021, 10.1093\/eurjpc\/zwab043","journal-title":"Eur J Prev Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective","volume":"383","author":"Mahmood SS","year":"2014","unstructured":"Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014, 383:999-1008. 10.1016\/S0140-6736(13)61752-3","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri A","year":"2020","unstructured":"Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. Arterioscler Thromb Vasc Biol. 2020, 40:301-8. 10.1161\/ATVBAHA.119.313353","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito Y","year":"2013","unstructured":"Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013, 97:135-8. 10.1007\/s12185-012-1222-7","journal-title":"Int J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey AK","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, et al.. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018, 71:e1-8. 10.1161\/HYPERTENSIONAHA.117.10271","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi JJ","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016, 375:1457-67. 10.1056\/NEJMra1100265","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi JJ","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015, 33:4210-8. 10.1200\/JCO.2015.62.4718","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren FL","year":"2021","unstructured":"Visseren FL, Mach F, Smulders YM, et al.. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, 42:3227-337. 10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.02.006","article-title":"Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib","volume":"42","author":"Glodkowska-Mrowka E","year":"2014","unstructured":"Glodkowska-Mrowka E, Mrowka P, Basak GW, et al.. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol. 2014, 42:439-47. 10.1016\/j.exphem.2014.02.006","journal-title":"Exp Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215543","article-title":"Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors","volume":"13","author":"Jang HJ","year":"2021","unstructured":"Jang HJ, Woo YM, Naka K, et al.. Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors. Cancers (Basel). 2021, 13:5543. 10.3390\/cancers13215543","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger MW","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, et al.. Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020, 18:1385-415. 10.6004\/jnccn.2020.0047","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95898-a-new-paradigm-of-cardio-hematological-monitoring-in-chronic-myeloid-leukemia-patients-treated-with-tyrosine-kinase-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:04Z","timestamp":1707507844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95898-a-new-paradigm-of-cardio-hematological-monitoring-in-chronic-myeloid-leukemia-patients-treated-with-tyrosine-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.25766","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}